Literature DB >> 35529087

The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis.

James M Luther1, Agnes B Fogo2.   

Abstract

Chronic kidney disease is characterized by progressive scarring that results in loss of normal tissue in the kidney and eventually end-stage kidney disease. Interstitial fibrosis and tubular atrophy have been most closely correlated with decline in renal function. Potential mechanisms include profibrotic changes in tubules, influx of profibrotic rather than healing reparative macrophages, and an increase in activated myofibroblasts. Aldosterone activates the mineralocorticoid receptor in the collecting duct to increase sodium reabsorption, resulting in increased blood pressure. Aldosterone also promotes inflammation and fibrosis in the kidney by activating the mineralocorticoid receptor in other cellular compartments, including podocytes, mesangial cells, epithelial cells, and myeloid cells. Aldosterone also may act indirectly by stimulating factors in epithelial tissues that contribute to inflammatory macrophage polarization, myofibroblast differentiation, and progressive fibrosis. This review discusses the potential mechanisms by which aldosterone and mineralocorticoid receptor activation promotes inflammation and fibrosis via nonclassical pathways in the kidney.
© 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aldosterone; chronic kidney disease; end-stage kidney disease; fibrosis; inflammation; mineralocorticoid receptor

Year:  2022        PMID: 35529087      PMCID: PMC9073221          DOI: 10.1016/j.kisu.2021.11.006

Source DB:  PubMed          Journal:  Kidney Int Suppl (2011)        ISSN: 2157-1716


  49 in total

Review 1.  Renal interstitial fibrosis: mechanisms and evaluation.

Authors:  Alton B Farris; Robert B Colvin
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

2.  Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.

Authors:  Eileen R Blasi; Ricardo Rocha; Amy E Rudolph; Eric A G Blomme; Melissa L Polly; Ellen G McMahon
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-β responsiveness of T cells.

Authors:  Barbara Schreier; Sindy Rabe; Bettina Schneider; Stefanie Ruhs; Claudia Grossmann; Steffen Hauptmann; Manfred Blessing; Joachim Neumann; Michael Gekle
Journal:  Hypertens Res       Date:  2011-02-24       Impact factor: 3.872

4.  Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury.

Authors:  Beom Jin Lim; Jae Won Yang; Jun Zou; Jianyong Zhong; Taiji Matsusaka; Ira Pastan; Ming-Zhi Zhang; Raymond C Harris; Hai-Chun Yang; Agnes B Fogo
Journal:  Kidney Int       Date:  2017-07-12       Impact factor: 10.612

5.  GM-CSF Promotes Macrophage Alternative Activation after Renal Ischemia/Reperfusion Injury.

Authors:  Sarah C Huen; Larry Huynh; Arnaud Marlier; Yashang Lee; Gilbert W Moeckel; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2014-11-11       Impact factor: 10.121

Review 6.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.

Authors:  Michael G Usher; Sheng Zhong Duan; Christine Y Ivaschenko; Ryan A Frieler; Stefan Berger; Günther Schütz; Carey N Lumeng; Richard M Mortensen
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

8.  The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.

Authors:  Jonatan Barrera-Chimal; Gabriel R Estrela; Sebastian M Lechner; Sébastien Giraud; Soumaya El Moghrabi; Shiem Kaaki; Peter Kolkhof; Thierry Hauet; Frédéric Jaisser
Journal:  Kidney Int       Date:  2018-03-13       Impact factor: 10.612

9.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

10.  Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.

Authors:  James M Luther; Pengcheng Luo; Zuofei Wang; Samuel E Cohen; Hyung-Suk Kim; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

View more
  4 in total

Review 1.  Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease.

Authors:  Toshifumi Nakamura; Sophie Girerd; Frederic Jaisser; Jonatan Barrera-Chimal
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 2.  Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

Authors:  Peter Rossing
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 3.  The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets.

Authors:  Morley D Hollenberg; Murray Epstein
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

4.  Macrophages in Renal Injury, Repair, Fibrosis Following Acute Kidney Injury and Targeted Therapy.

Authors:  Hui Chen; Na Liu; Shougang Zhuang
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.